NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2025 Management View CEO Dave Rosa highlighted the strong performance of the OneRF ablation system, which is the first FDA-cleared product ...

Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from ...

Zimmer Biomet recently announced entering a definitive agreement to acquire all outstanding common shares of Paragon 28. Under the agreement, ...

Dave Rosa; President, Chief Executive Officer, Director; Neuroone Medical Technologies Corp. Ron McClurg; Chief Financial Officer; Neuroone Medical Technologies Corp ...

Reports Q1 product revenue $3.3M vs. $1M last year. Reports Q1 license revenue $3M vs. $0 last year. “This quarter marks the next step forward ...

Stock analysts at Roth Capital issued their Q1 2025 earnings estimates for Zimmer Biomet in a research note issued on Friday, February 7th. Roth Capital analyst J. Wittes forecasts that the medical ...

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Q1 2025 Earnings Call Transcript February 12, 2025 NeuroOne Medical Technologies Corporation beats earnings expectations. Reported EPS is ...

Zimmer Biomet provided 2025 guidance of constant currency ... supported by increased penetration of the Persona portfolio and ROSA Robotics. Hips grew 4%, bolstered by the initial rollout of ...

Shares of Zimmer Biomet Holdings Inc. ZBH slipped 1.43% to $98.98 Tuesday, on what proved to be an all-around great trading ...

Zimmer Biomet posted fourth-quarter revenue growth of 5% in constant currency, which is generally consistent with the preceding quarters in 2024. Why it matters: As Zimmer Biomet has pursued a ...

Zimmer Biomet (NYSE: ZBH) shares dipped slightly today on fourth-quarter results that came in just ahead of the consensus ...